BIOS

Bioplus Acquisition Corp

A blank-check company, or SPAC, formed to take a private life-sciences or biotechnology business public through a merger. It held its initial public offering in late 2021 and planned to combine with Avertix Medical, but that deal fell through in 2023, after which the company dissolved and returned its funds to shareholders. Its name echoes the "bio" of life sciences, though it should not be confused with the separate specialty pharmacy also called BioPlus.

Common Stock — Liquidated Oct 2023

No Schedule 13D or 13G filings recorded.